Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

NIH grant to the University of Central Florida to conduct research on aphasia

A new University of Central Florida study could help tens of thousands of Chinese-Americans who have difficulty speaking after they suffer from strokes or other illnesses.

9 Oct 2009

Physician shortage affects older Americans' access to basic care

As members of Congress debate what form a national health care plan should take, older Americans continue to suffer the consequences of a physician shortage that makes accessing basic care a struggle. Barriers to care could be greatly eased, however, by legislation that lifts restrictions preventing physician assistants (PAs) from treating Medicare patients.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

Applied NeuroSolutions, Inc.(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples.

9 Oct 2009

New findings highlight potential role of copper in Alzheimer's disease

New research has shown that there could be a protective role for copper in Alzheimer's disease.

9 Oct 2009

Emisphere Technologies announces commercial launch of oral Eligen B12

Emisphere Technologies, Inc. today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.

8 Oct 2009

First Edition: October 8, 2009

Today's headlines reflect yesterday's big health reform news: The CBO's revised cost analysis is good news for the Baucus bill.

8 Oct 2009

NIH awards a $2.2M grant to biochemist for a high-resolution electron microscope

Waltham, MA-Researchers' ability to rapidly detect the macromolecular protein clumps implicated in Alzheimer's and other neurodegenerative diseases will soon get a sizable boost in the lab of biochemist and Howard Hughes Medical Investigator Nikolaus Grigorieff. The National Institutes of Health has just awarded Grigorieff a $2.2 million grant for a second high-resolution electron microscope (EM) in his lab.

8 Oct 2009

"Health This Week" television program shows how people are exploring to live better, healthier and longer lives

Health This Week with Donald Baillargeon is an internationally syndicated television program about the many ways people are exploring to live better, healthier and longer lives.

8 Oct 2009

PP5 enzyme decrease in neurons can cause cell death in Alzheimer's disease patients

A Purdue University researcher has discovered that the amount of an enzyme present in neurons can affect the mechanism thought to cause cell death in Alzheimer's disease patients and may have applications for other diseases such as stroke and heart attack.

8 Oct 2009

Study reveals large structural differences between natural prions and man-made synthetic analogs

A collaboration between scientists at Vanderbilt University and the University of California, San Francisco has led to the first direct information about the molecular structure of prions. In addition, the study has revealed surprisingly large structural differences between natural prions and the closest synthetic analogs that scientists have created in the lab.

7 Oct 2009

HDSA honors outstanding contributors against Huntington's Disease

The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday.

7 Oct 2009

Research and development using stem cells from menstrual blood helps fight against breast cancer

Cryo-Cell International, a global leader in stem cell innovation, is proud to be making progress in the fight against breast cancer through research and development using stem cells from menstrual blood.

7 Oct 2009

New findings on Alzheimer's disease suggest a possible way for treatment

The action of a small protein that is a major villain in Alzheimer's disease can be counterbalanced with another brain protein, researchers at UT Southwestern Medical Center have found in an animal study.

7 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

Study reveals information about molecular structure of prions

6 Oct 2009

Key defence mechanism used by the immune system against Listeria identified

A team of University of British Columbia microbiologists has identified a key defence mechanism used by the immune system against Listeria with strong implications for the future development of vaccines.

6 Oct 2009

Drivers with Parkinson's disease at greater risk of crashes on foggy days

Drivers with mild to moderate Parkinson's disease may be at higher risk of crashes on foggy days and other times of low visibility. The research, involving a driving simulation test, is published in the October 6, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

6 Oct 2009

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

NIH grant to the University of Central Florida to conduct research on aphasia

Physician shortage affects older Americans' access to basic care

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

New findings highlight potential role of copper in Alzheimer's disease

Emisphere Technologies announces commercial launch of oral Eligen B12

First Edition: October 8, 2009

NIH awards a $2.2M grant to biochemist for a high-resolution electron microscope

"Health This Week" television program shows how people are exploring to live better, healthier and longer lives

PP5 enzyme decrease in neurons can cause cell death in Alzheimer's disease patients

Study reveals large structural differences between natural prions and man-made synthetic analogs

HDSA honors outstanding contributors against Huntington's Disease

Research and development using stem cells from menstrual blood helps fight against breast cancer

New findings on Alzheimer's disease suggest a possible way for treatment

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

Study reveals information about molecular structure of prions

Key defence mechanism used by the immune system against Listeria identified

Drivers with Parkinson's disease at greater risk of crashes on foggy days

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in